Vertex claimed the two drugs in the deal could eventually bring in more than $5 billion annually. Still, the high price it paid stirred debate among analysts and investors.
Vertex to acquire CRNX for $10B, adding approved rare disease drug Palsonify and late-stage pipeline assets to expand its endocrinology portfolio.
San Diego-based Crinetics Pharmaceuticals is being acquired by Boston’s Vertex Pharmaceuticals for $10 billion — the largest ...
You can lower your cortisol levels by getting enough sleep and exercising regularly.
This buy gives Vertex both a recently-commercialized drug, and a very strong lead candidate.
Morning Overview on MSN
The FDA warns some arthritis supplements hide prescription steroids inside the bottle
People reaching for over-the-counter joint-pain capsules at major retailers have unknowingly swallowed prescription-strength ...
Vertex Pharma to buy Crinetics Pharmaceuticals for $10 billion: Boston Wednesday, July 8, 2026, 14:00 Hrs [IST] Vertex Pharmaceuticals Incorporated, a global biotechnology company ...
In a cohort of patients with difficult-to-control type 2 diabetes, more than 75% had elevated cortisol at a level that has ...
Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.
'Cortisol is not behind your slight weight gain' ...
Additional blockbuster drugs may be on the horizon.
Vertex Pharmaceuticals Incorporated’s $10B Crinetics Pharmaceuticals, Inc. buy adds PALSONIFY & a Phase 3 CAH asset. Click for more on VRTZX and CRNX stock.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results